Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis

This study is testing a combination of three drugs — SHR-A1811 (an antibody-drug combination), pyrotinib (a targeted HER2 blocker), and bevacizumab (a drug that cuts off tumor blood supply) — in patients with advanced breast cancer that has spread to the brain. The goal is to see if this combination can treat brain tumors that have not yet been irradiated. **You may be eligible if...** - You are over 18 years old - You have breast cancer with brain metastases confirmed by MRI, with at least one measurable brain lesion - The brain tumors have not previously been treated with radiation - Your overall physical condition is adequate (ECOG 0-2) - Your life expectancy is at least 3 months - Your organ function and blood counts are adequate **You may NOT be eligible if...** - You have cancer that has spread to the membranes around the brain (leptomeningeal disease) - You have uncontrolled fluid buildup in body cavities (e.g., large amounts of fluid around the lungs) - You have brain complications that are not responding to treatment - You have rapidly progressing neurological symptoms or uncontrolled seizures Talk to your doctor to see if this trial is right for you.